ORIC Shares Slide on Higher-Dose Side Effects — But 400mg Rinzimetostat Looks Best-in-Class
ORIC shares plunged after Phase 1b data showed higher side effects at 600mg rinzimetostat.
/ 1659 items
#XY↓
ImmunityBio Scores $100 Million Cash Boost – $75M Non-Dilutive – to Supercharge Global Expansion
ImmunityBio strengthens its balance sheet with $100 million financing, including $75M non-dilutive funding from Oberland Capital and $25M debt conversion.
FDA Moving to Bring Back Popular Injectable Peptides
The FDA is moving to allow compounding pharmacies to produce over a dozen banned injectable peptides. RFK Jr. says he's a big fan and has used them with great results.
Agios Moves Closer to Fast FDA Approval for New Sickle Cell Pill
Agios is pursuing accelerated FDA approval for mitapivat, a new oral pill for sickle cell disease. The RISE UP trial showed better hemoglobin levels, fewer pain crises, and good safety.
Oppenheimer Sees $1 Billion Potential in Passage Bio’s PBFT02 for FTD
Oppenheimer just started coverage on Passage Bio with an Outperform rating and $30 price target. They call the recent pullback a buying opportunity ahead of key PBFT02 data in H1 2026.
Caribou Biosciences Jumps as FDA Grants RMAT Designation to Off-the-Shelf CAR-T Therapy CB-011 for Multiple Myeloma
Caribou Biosciences stock surges after FDA grants RMAT designation to CB-011, its off-the-shelf allogeneic CAR-T for multiple myeloma. Phase 1 data: 92% ORR, 75% complete response in BCMA-naïve patients. More data expected 2026.